Abstract:The highly polymorphic human cytochrome P450 2D6 (CYP2D6) metabolizes about 25% of currently used drugs. In this study, we have explored the interaction of a large number of substrates (n = 120) with wild-type and mutated CYP2D6 by molecular docking using the CDOCKER module. Before we conducted the molecular docking and virtual mutations, the pharmacophore and QSAR models of CYP2D6 substrates were developed and validated. Finally, we explored the interaction of a traditional Chinese herbal formula, Fangjifuling decoction, with CYP2D6 by virtual screening. The optimized pharmacophore model derived from 20 substrates of CYP2D6 contained two hydrophobic features and one hydrogen bond acceptor feature, giving a relevance ratio of 76% when a validation set of substrates were tested. However, our QSAR models gave poor prediction of the binding affinity of substrates. Our docking study demonstrated that 117 out of 120 substrates could be docked into the active site of CYP2D6. Forty one out of 117 substrates (35.04%) formed hydrogen bonds with various active site residues of CYP2D6 and 53 (45.30%) substrates formed a strong pi-pi interaction with Phe120 (53/54), with only carvedilol showing pi-pi interaction with Phe483. The active site residues involving hydrogen bond formation with substrates included Leu213, Lys214, Glu216, Ser217, Gln244, Asp301, Ser304, Ala305, Phe483, and Phe484. Furthermore, the CDOCKER algorithm was further applied to study the impact of mutations of 28 active site residues (mostly non-conserved) of CYP2D6 on substrate binding modes using five probe substrates including bufuralol, debrisoquine, dextromethorphan, sparteine, and tramadol. All mutations of the residues examined altered the hydrogen bond formation and/or aromatic interactions, depending on the probe used in molecular docking. Apparent changes of the binding modes have been observed with the Glu216Asp and Asp301Glu mutants. Overall, 60 compounds out of 130 from Fangjifuling decoction matched our pharmacophore model for CYP2D6 substrates. Fifty four out of these 60 compounds could be docked into the active site of CYP2D6 and 24 of 54 compounds formed hydrogen bonds with Glu216, Asp301, Ser304, and Ala305 in CYP2D6. These results have provided further insights into the factors that determining the binding modes of substrates to CYP2D6. Screening of high-affinity ligands for CYP2D6 from herbal formula using computational models is a useful approach to identify potential herb-drug interactions.

Identification of CYP2C19 Inhibitors from Phytochemicals Using the Recombinant Human Enzyme Model.

Co-expression Model and Inhibitor Screening of the Human P450 CYP2C19 with the CYPOR and CYPb5

Investigation on Modulation of Human Cytochrome P450 and P-glycoprotein by Herb or Natural Product Using in Vivo Probe Substrate

Computational and in Vitro Studies on the Inhibitory Effects of Herbal Compounds on Human Cytochrome P450 1A2

Inhibitory Effects of Phytochemicals on Metabolic Capabilities of CYP2D6()1 and CYP2D6()10 Using Cell-Based Models in Vitro.

Novel Natural Inhibitors Of Cyp1a2 Identified By In Silico And In Vitro Screening

[Establishment of in Vitro Evaluation Model for CYP2B6 Induction and Its Application to Screen Inducers among TCMs].

The inhibitory effect of 225 frequently-used traditional Chinese medicines for CYP3A4 metabolic enzyme by isoform-specific probe

Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1

Identification of new probe substrates for human CYP20A1.

Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates

Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes

Expression and Enzymatic Analysis of the Human Cytochrome CYP1A2 in Saccharomyces cerevisiae

Evaluation of the Effects of 18 Non-Synonymous Single-Nucleotide Polymorphisms of CYP450 2C19 on in Vitro Drug Inhibition Potential by a Fluorescence-Based High-Throughput Assay.

A High-Throughput Inhibition Screening Of Major Human Cytochrome P450 Enzymes Using An In Vitro Cocktail And Liquid Chromatography-Tandem Mass Spectrometry

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2j2 Inhibitors

Rapid Determination of Six Metabolites from Multiple Cytochrome P450 Probe Substrates in Human Liver Microsome by Liquid Chromatography/Mass Spectrometry: Application to High-Throughput Inhibition Screening of Terpenoids

A Novel System for Evaluating the Inhibition Effect of Drugs on Cytochrome P450 Enzymes in vitro Based on Human-Induced Hepatocytes (hiHeps)

Pharmacophore, Qsar, and Binding Mode Studies of Substrates of Human Cytochrome P450 2d6 (cyp2d6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening

Identification of New Substrates and Inhibitors of Human CYP2A7